Shibani Pati: Freeze Dried Platelet Derived Biologic for TBI
Shibani Pati, Professor and Vice Chair at UCSF, Professor Department of Surgery at University of California, shared Levi Gadye’s post on LinkedIn about a recent article she and her colleagues co-authored, published in Blood, adding:
“Freeze dried platelet derived biologic for TBI
I’m excited to share our new paper published in Blood, highlighting the therapeutic potential of a first-in-class freeze-dried platelet–derived biologic (FPH, also known as Thrombosome).
Remarkably, this agent not only demonstrated hemostatic activity but also attenuated neuroinflammation, reduced cerebral vascular leak, and limited intracranial hemorrhage in a well-established murine model of TBI.
I’m deeply grateful to our collaborators at Cellphire Therapeutics for their partnership, and to the U.S. Department of Defense for their visionary support of this work.
This study reflects the strength of an exceptional team effort – special recognition to first author Huimin Geng, Mahuvakar Alpa Trivedi and the outstanding contributions from Callie Keane, Byron Miyazawa Haoqian Zhang, Longh ui Qiu, Daniel Potter, Austin Edwards, Lindsay Vivona, Maximillian Lin, Simon Cleary, Alison Nair, and G. Michael Fitzpatrick, Mark Looney.
TBI is the leading killer in all individuals under the age of 44 and in children over the age of 1 – with few effective interventions for both acute and long-term out comes.
Most of the approach to TBI follows a watch, wait and hope paradigm. This is not good enough in the context of global blood product shortages – and with hemorrhage remaining the leading cause of preventable death – a dried, shelf-stable biologic that combines hemostatic and organ-protective properties, has the potential to transform care for critically injured patients.
These findings strongly support the urgent need for clinical translation and a phase 1 trial, particularly in traumatic brain injury.
Kudos to the DoD for their foresight in advancing next-generation blood products.
Shibani Pati
Corresponding Author”
Levi Gadye, Senior Public Information Representative at University of California, shared a post on LinkedIn:
“A product made from freeze-dried platelets that could be stored in ambulances might change what traumatic brain injury (TBI) means for millions.
It was invented to stop bleeding on the battlefield, like a molecular tourniquet, and it’s currently in Phase II clinical trials for trauma, surgery, and blood disorders. (Its trade name is Thrombosomes). It has a shelf life of years at room temp.
A UCSF team led by Shibani Pati and Alpa Trivedi tested it on blood vessel cells in petri dishes and found that it reinforced layers of the cells and artificially-grown blood vessels.
So the scientists treated a mouse model of TBI with the product and what they saw made them scream.
TBI typically does two things in the brain:
- It bursts blood vessels, leading to acute bleeding
- It weakens other blood vessels, resulting in leakage and swelling (edema)
The product stopped both when given at 1hr or 24hr after TBI in the mice. It also reduced inflammation. The images (and videos) speak for themselves – check them out in the story.
If it someday is approved for TBI, it would be the first-ever TBI therapy.”
Title: A Dried Platelet-Derived Biologic for Blood-Brain Barrier Repair and Hemorrhage Control Following TBI in Mice
Authors: Alpa Trivedi, Byron Y Miyazawa, Haoqian Zhang, Longhui Qiu, Daniel Potter, Austin William Edwards, Lindsay Vivona, Maximillian Lin, Callie Keane, Huimin Geng, Simon J Cleary, Alison Nair, Michael M Fitzpatrick, Mark R. Looney, Shibani Pati

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support